DE60137829D1 - Menschliche stra6 polypeptide - Google Patents

Menschliche stra6 polypeptide

Info

Publication number
DE60137829D1
DE60137829D1 DE60137829T DE60137829T DE60137829D1 DE 60137829 D1 DE60137829 D1 DE 60137829D1 DE 60137829 T DE60137829 T DE 60137829T DE 60137829 T DE60137829 T DE 60137829T DE 60137829 D1 DE60137829 D1 DE 60137829D1
Authority
DE
Germany
Prior art keywords
polypeptides
present
nucleic acid
stra6 polypeptide
human stra6
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60137829T
Other languages
English (en)
Inventor
Diane Pennica
Victoria Smith
William I Wood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of DE60137829D1 publication Critical patent/DE60137829D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
DE60137829T 2000-01-13 2001-01-11 Menschliche stra6 polypeptide Expired - Lifetime DE60137829D1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US17584900P 2000-01-13 2000-01-13
US19708900P 2000-04-14 2000-04-14
US22891400P 2000-08-29 2000-08-29
PCT/US2001/000847 WO2001051635A2 (en) 2000-01-13 2001-01-11 Novel stra6 polypeptides

Publications (1)

Publication Number Publication Date
DE60137829D1 true DE60137829D1 (de) 2009-04-16

Family

ID=27390600

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60137829T Expired - Lifetime DE60137829D1 (de) 2000-01-13 2001-01-11 Menschliche stra6 polypeptide

Country Status (15)

Country Link
US (7) US7173115B2 (de)
EP (1) EP1246917B1 (de)
JP (2) JP2003519491A (de)
KR (2) KR20080006002A (de)
CN (2) CN1425066B (de)
AT (1) ATE424457T1 (de)
AU (2) AU785055B2 (de)
CA (1) CA2397207C (de)
DE (1) DE60137829D1 (de)
DK (1) DK1246917T3 (de)
ES (1) ES2323220T3 (de)
IL (2) IL150676A0 (de)
NZ (1) NZ520095A (de)
PT (1) PT1246917E (de)
WO (1) WO2001051635A2 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL150676A0 (en) * 2000-01-13 2003-02-12 Genentech Inc NOVEL STRa6 POLYPEPTIDES
EP1334126A1 (de) * 2000-03-23 2003-08-13 Curagen Corporation Menschliches stra6-ähnliches protein und dafür kodierende nukleinsäure
CN1339489A (zh) * 2000-08-23 2002-03-13 上海博德基因开发有限公司 一种新的多肽——人视黄酸效应蛋白53.57和编码这种多肽的多核苷酸
NZ524230A (en) * 2000-08-29 2006-05-26 Genentech Inc Identification of tumor antigens the expression of which is selectively enhanced by retinoid treatment
WO2002088081A2 (en) * 2001-05-01 2002-11-07 The Regents Of The University Of California Wnt and frizzled receptors as targets for immunotherapy in head and neck squamous cell carcinomas
ES2685702T3 (es) * 2002-03-13 2018-10-10 Genomic Health, Inc. Obtención de perfil de expresión génica en tejidos tumorales biopsiados
US7666627B2 (en) * 2002-08-08 2010-02-23 Targetex Kft. Folded recombinant catalytic fragments of multidomain serine proteases, preparation and uses thereof
WO2004039412A2 (en) * 2002-10-29 2004-05-13 Engene, Inc. Compositions for cancer treatment
CN101955524A (zh) * 2003-04-30 2011-01-26 森托科尔奥索生物科技公司 Cngh0010特异性的多核苷酸、多肽、抗体、组合物、方法和用途
US7763067B2 (en) * 2004-09-01 2010-07-27 C. R. Bard, Inc. Stent and method for manufacturing the stent
US20090048196A1 (en) * 2007-01-18 2009-02-19 The Regents Of The University Of California Membrane receptor for retinol binding protein mediates cellular uptake of vitamin A, methods of use and compositions
WO2010008427A1 (en) * 2008-04-11 2010-01-21 Ludwig Institute For Cancer Research Ltd. Tryptophan catabolism in cancer treatment and diagnosis
EP2445539A4 (de) * 2009-06-26 2015-05-20 Five Prime Therapeutics Inc Therapeutische antikörper-zielvalidierung und in vivo-screening
WO2011085263A2 (en) 2010-01-11 2011-07-14 Genomic Health, Inc. Method to use gene expression to determine likelihood of clinical outcome of renal cancer
AU2011282892B2 (en) * 2010-07-27 2015-07-16 Mdxhealth Sa Method for using gene expression to determine prognosis of prostate cancer
NZ722902A (en) 2012-01-31 2017-12-22 Genomic Health Inc Gene expression profile algorithm and test for determining prognosis of prostate cancer
US20130209473A1 (en) 2012-02-11 2013-08-15 Genentech, Inc. R-spondin translocations and methods using the same
SG10201709537PA (en) 2013-05-30 2017-12-28 Genomic Health Inc Gene expression profile algorithm for calculating a recurrence score for a patient with kidney cancer
EP3636661A1 (de) * 2018-10-12 2020-04-15 Bioc3 Phosphate translocator

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4444545A (en) * 1982-04-08 1984-04-24 Sanders David F Pump control system
US4943529A (en) 1982-05-19 1990-07-24 Gist-Brocades Nv Kluyveromyces as a host strain
US4485054A (en) * 1982-10-04 1984-11-27 Lipoderm Pharmaceuticals Limited Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
US4870009A (en) 1982-11-22 1989-09-26 The Salk Institute For Biological Studies Method of obtaining gene product through the generation of transgenic animals
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
AU2353384A (en) 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
AU3145184A (en) 1983-08-16 1985-02-21 Zymogenetics Inc. High expression of foreign genes in schizosaccharomyces pombe
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4736866A (en) 1984-06-22 1988-04-12 President And Fellows Of Harvard College Transgenic non-human mammals
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
EP0272253A4 (de) 1986-03-07 1990-02-05 Massachusetts Inst Technology Verfahren zur verbesserung der glykoproteinstabilität.
US4676417A (en) * 1986-04-14 1987-06-30 Richard Hirschkoff Ski carrier
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US5010182A (en) 1987-07-28 1991-04-23 Chiron Corporation DNA constructs containing a Kluyveromyces alpha factor leader sequence for directing secretion of heterologous polypeptides
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US4997852A (en) * 1987-08-26 1991-03-05 Ohio State University Research Foundation Method and composition for achieving cancer chemopreventive and chemotherapeutic activity
IL87737A (en) 1987-09-11 1993-08-18 Genentech Inc Method for culturing polypeptide factor dependent vertebrate recombinant cells
DE3889546T2 (de) 1987-12-21 1994-09-08 Univ Toledo Transformation von keimenden pflanzensamen mit hilfe von agrobacterium.
SE8802525L (sv) 1988-07-06 1990-01-07 Fmg Filipstad Ab Stol
AU4005289A (en) 1988-08-25 1990-03-01 Smithkline Beecham Corporation Recombinant saccharomyces
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5009772A (en) 1989-02-27 1991-04-23 Kerr-Mcgee Corporation Solvent extraction process
ES2038579T3 (es) 1989-04-28 1997-02-16 Rhein Biotech Proz & Prod Gmbh Celulas de levadura del genero schwanniomyces.
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
CA2055435A1 (en) 1989-05-10 1990-11-11 Eli Gilboa Stably transformed eucaryotic cells comprising a foreign transcribable dna under the control of a pol iii promoter
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
EP0479909B1 (de) 1989-06-29 1996-10-30 Medarex, Inc. Bispezifische reagenzien für die aids-therapie
FR2649120B1 (fr) 1989-06-30 1994-01-28 Cayla Nouvelle souche et ses mutants de champignons filamenteux, procede de production de proteines recombinantes a l'aide de ladite souche et souches et proteines obtenues selon ce procede
WO1991004753A1 (en) 1989-10-02 1991-04-18 Cetus Corporation Conjugates of antisense oligonucleotides and therapeutic uses thereof
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
JP2938569B2 (ja) 1990-08-29 1999-08-23 ジェンファーム インターナショナル，インコーポレイティド 異種免疫グロブリンを作る方法及びトランスジェニックマウス
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
CA2122732C (en) 1991-11-25 2008-04-08 Marc D. Whitlow Multivalent antigen-binding proteins
US5731167A (en) 1992-01-17 1998-03-24 The United States Of America As Represented By The Department Of Health And Human Services Autotaxin: motility stimulating protein useful in cancer diagnosis and therapy
US5756448A (en) 1992-02-26 1998-05-26 The General Hospital Corporation Constitute activator of retinoid (CAR) receptor polypeptides
ES2161715T3 (es) 1992-03-04 2001-12-16 Univ California Hibridacion genomica comparativa (hgc).
WO1994011026A2 (en) 1992-11-13 1994-05-26 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma
PT674506E (pt) 1992-12-02 2001-01-31 Alkermes Inc Microsferas contendo hormona de crescimento com libertacao controlada
US5547947A (en) * 1993-03-11 1996-08-20 Hoffmann-La Roche Inc. Methods of treatment
PT616812E (pt) 1993-03-24 2000-04-28 Berlex Biosciences Combinacao de compostos anti-hormonais e moleculas de ligacao no tratamento do cancro
WO1996007399A1 (en) 1994-09-09 1996-03-14 Takeda Chemical Industries, Ltd. Sustained release preparation containing metal salt of a peptide
US5681860A (en) * 1993-09-21 1997-10-28 The Trustees Of Columbia University In The City Of New York Method of increasing expression of HLA, cell surface and TAA antigens of cells using 3-(N-acetylamino)-5-(N-decyl-N-methylamino)-benzyl alcohol
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6316007B1 (en) 1995-04-04 2001-11-13 Wound Healing Of Oklahoma Combined physical and immunotherapy for cancer
PL184531B1 (pl) 1995-06-07 2002-11-29 Alkermes Inc Kompozycja o opóźnionym uwalnianiu ludzkiego hormonu wzrostu do wytwarzania leku do terapii
ZA965368B (en) 1995-07-14 1997-01-14 Novo Nordisk As A pharmaceutical formulation
US5871697A (en) * 1995-10-24 1999-02-16 Curagen Corporation Method and apparatus for identifying, classifying, or quantifying DNA sequences in a sample without sequencing
US6458939B1 (en) 1996-03-15 2002-10-01 Millennium Pharmaceuticals, Inc. Compositions and methods for the diagnosis, prevention, and treatment of neoplastic cell growth and proliferation
US6525174B1 (en) * 1997-06-06 2003-02-25 Human Genome Sciences, Inc. Precerebellin-like protein
EP1039801A4 (de) * 1997-06-06 2003-03-26 Human Genome Sciences Inc 207 menschliche sekretierte proteine
EP1206536A2 (de) * 1999-08-17 2002-05-22 Sagami Chemical Research Center Menschliche proteine mit hydrophoben domänen und dafür kodierende dnas
IL150676A0 (en) * 2000-01-13 2003-02-12 Genentech Inc NOVEL STRa6 POLYPEPTIDES
EP1334126A1 (de) * 2000-03-23 2003-08-13 Curagen Corporation Menschliches stra6-ähnliches protein und dafür kodierende nukleinsäure
US7301008B2 (en) * 2000-06-05 2007-11-27 Genentech, Inc. PRO7174 polypeptides
US20030187201A1 (en) * 2000-09-15 2003-10-02 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030120040A1 (en) * 2001-06-29 2003-06-26 Genentech, Inc. Secreted and Transmembrane polypeptides and nucleic acids encoding the same

Also Published As

Publication number Publication date
WO2001051635A3 (en) 2002-05-02
AU2006241374B2 (en) 2009-10-22
US20020173461A1 (en) 2002-11-21
CA2397207C (en) 2013-12-03
WO2001051635A2 (en) 2001-07-19
CN1425066B (zh) 2010-05-26
US20090010936A1 (en) 2009-01-08
KR20080006002A (ko) 2008-01-15
EP1246917A2 (de) 2002-10-09
US7939650B2 (en) 2011-05-10
EP1246917B1 (de) 2009-03-04
AU3276801A (en) 2001-07-24
JP2003519491A (ja) 2003-06-24
JP5701624B2 (ja) 2015-04-15
ATE424457T1 (de) 2009-03-15
US7855278B2 (en) 2010-12-21
US7173115B2 (en) 2007-02-06
IL150676A (en) 2010-05-17
US7741439B2 (en) 2010-06-22
KR100929057B1 (ko) 2009-11-30
IL150676A0 (en) 2003-02-12
CN1425066A (zh) 2003-06-18
US20020156252A1 (en) 2002-10-24
US20110171238A1 (en) 2011-07-14
CN101643733A (zh) 2010-02-10
PT1246917E (pt) 2009-06-02
NZ520095A (en) 2004-05-28
ES2323220T3 (es) 2009-07-09
US20070025998A1 (en) 2007-02-01
JP2011103891A (ja) 2011-06-02
DK1246917T3 (da) 2009-06-08
KR20020073168A (ko) 2002-09-19
AU2006241374A1 (en) 2006-12-14
US20070128188A1 (en) 2007-06-07
AU785055B2 (en) 2006-09-07
US20080299547A1 (en) 2008-12-04
CA2397207A1 (en) 2001-07-19

Similar Documents

Publication Publication Date Title
ATE447583T1 (de) Polypeptide und dafür kodierende nukleinsäure
DE60137829D1 (de) Menschliche stra6 polypeptide
CY1112334T1 (el) Ομολογα πολυπεπτιδια il-17 και θεραπευτικες χρησεις αυτων
ATE478145T1 (de) Sekretierte und transmembran polypeptide und dafür kodierende nukleinsäuren
DK1616878T3 (da) Udskilte og membranspændende polypeptider samt nukleinsyrer kodende for disse
DK1366161T3 (da) Antagonist anti-PRO842-antistof
WO2003076569A3 (en) Novel polypeptides having sequence similarity to gdnfr and nucleic acids encoding the same
EP1241179A3 (de) Menschliches Cornichon-ähliches Protein und dafür kodierende Nukleinsäure
DK1241251T3 (da) Humant prostasin-lignende protein og nukleinsyrer kodende for samme
EP1251139A3 (de) Menschliches mindin-ähliches Protein und dafür kodierende Nukleinsäure
ATE402954T1 (de) Menschliches a33-antigen-ähnliches protein und dafür kodierende nukleinsäure
ATE405590T1 (de) Menschliches hcar-ähnliches protein und dafür kodierende nukleinsäure
ATE404585T1 (de) Menschliches synaptogyrin-ähnliches protein und dafür kodierende nukleinsäure
ATE492640T1 (de) Loslösendes protein 5 - ucp5
DE60043258D1 (de) Menschliches suppressor von fused
DK1300417T3 (da) Secerneret og transmembrant polypeptid og nucleinsyre kodende derfor
EP1241252A3 (de) Menschliches Enteropeptidase-ähnliches Protein und dafür kodierende Nukleinsäure
EP1247817A3 (de) Menschliches CD-23-ähliches Protein und dafür kodierende Nukleinsäure
DK1191101T3 (da) PRO241 polypeptider og nucleinsyre kodende herfor
DE69827532D1 (de) Polypeptide und dafür kodierende Nukleinsäure
DE60038986D1 (de) Ausgeschiedene und Transmembranpolypeptide und dafür kodierende Nukleinsäure

Legal Events

Date Code Title Description
8364 No opposition during term of opposition